AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Auxl stock quote2/3/2024 ![]() ![]() I think Auxilium is worth considering for two main reasons. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. Currently Xiaflex is undergoing Phase III clinical trial for the treatment of Peyronie's Disease, Phase II clinical trial for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) as well as Phase I clinical trial for the treatment of cellulite (edematous fibrosclerotic panniculopathy). There are currently no other treatment options available for Dupuytren's Contracture apart from surgery.Īpart from Dupuytren's Contracture, Xiaflex has the potential to be the first-line treatment in multiple therapeutic areas. Xiaflex is an injectable collagenase clostridium histolyticum (CCH, in short) used for the treatment of Dupuytren's Contracture in adult patients with a palpable cord. Testim is a topical 1% testosterone once-a-day gel for the treatment of hypogonadism. Auxilium's lead two products are Testim and Xiaflex. ![]() In this investment thesis I will explain why the stock is worth buying at the current level with ~75% upside in the next one year.Īuxilium, together with its subsidiaries, develops and markets specialty pharmaceutical products worldwide. Currently Auxilium is consolidating just below $18, and I feel slowly but steadily the stock is heading towards $25 again. Since May the stock gradually started to build a positive momentum again after creating a 52-week low at $13.87. No cash balance or cash flow is included in the calculation.The stock of Auxilium Pharmaceuticals ( NASDAQ: AUXL), a specialty biopharmaceutical company, corrected almost 45% in the last 10 months from its 52-week high at $25.54 in the absence of any meaningful catalysts. Please note all regulatory considerations regarding the presentation of fees must be taken into account. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Actual performance may differ significantly from backtested performance. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. Certain assumptions have been made for modeling purposes and are unlikely to be realized. Changes in these assumptions may have a material impact on the backtested returns presented. ![]() General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested performance is not an indicator of future actual results. Disclaimer: The TipRanks Smart Score performance is based on backtested results.
0 Comments
Read More
Leave a Reply. |